# Harvard Bioscience (HBIO) — Earnings

HBIO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/hbio/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.14 |
| EPS estimate | −$0.21 |
| EPS surprise | +33.33% |
| Revenue surprise | +5.95% |
| Revenue | $22.7M |
| Revenue estimate | $21.4M |
| Reported | Aug 11, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1123494/000117184326005425/hbio20260630_10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/56cf38ed-c7ad-3c61-659c-a9150727d9ca.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 11, 2026 | −$0.21 | −$0.14 | 33.33% | $21.4M | $22.7M |
| Q1 2026 | May 12, 2026 | −$0.62 | −$0.33 | 46.77% | $21.2M | $20.8M |
| Q4 2025 | Mar 12, 2026 | $0.35 | $0.00 | -100.00% | $23.1M | $23.7M |
| Q3 2025 | Nov 6, 2025 | $0.05 | $0.00 | -100.00% | $20.0M | $20.6M |
| Q2 2025 | Aug 11, 2025 | −$0.25 | −$0.10 | 60.00% | $18.8M | $20.4M |
| Q1 2025 | May 12, 2025 | −$0.40 | −$0.10 | 75.00% | $19.2M | $21.8M |
| Q4 2024 | Mar 12, 2025 | $0.50 | $0.60 | 20.00% | $24.1M | $24.6M |
| Q3 2024 | Nov 7, 2024 | $0.15 | −$0.20 | -233.33% | $23.7M | $22.0M |
| Q2 2024 | Aug 8, 2024 | $0.50 | $0.00 | -100.00% | $26.4M | $23.1M |
| Q1 2024 | May 7, 2024 | $0.37 | $0.20 | -45.46% | $25.8M | $24.5M |
| Q4 2023 | Mar 7, 2024 | $0.50 | $0.40 | -20.00% | $29.1M | $28.2M |
| Q3 2023 | Nov 7, 2023 | $0.40 | $0.10 | -75.00% | $28.0M | $25.4M |
| Q2 2023 | Aug 8, 2023 | $0.60 | $0.40 | -33.33% | $29.5M | $28.8M |
| Q1 2023 | Apr 25, 2023 | $0.50 | $0.60 | 20.00% | $28.8M | $30.0M |
| Q4 2022 | Mar 9, 2023 | $0.33 | $0.40 | 20.01% | $30.3M | $28.4M |
| Q3 2022 | Nov 8, 2022 | $0.67 | −$0.10 | -115.00% | $28.9M | $26.9M |
| Q2 2022 | Aug 4, 2022 | $0.60 | $0.50 | -16.67% | $30.5M | $29.2M |
| Q1 2022 | May 4, 2022 | $0.45 | $0.40 | -11.11% | $28.8M | $28.8M |
| Q4 2021 | Mar 8, 2022 | $1.00 | $0.80 | -20.00% | $33.0M | $33.1M |
| Q3 2021 | Nov 3, 2021 | $0.50 | $0.60 | 20.00% | $27.9M | $29.7M |

## Frequently Asked Questions

### When did Harvard Bioscience (HBIO) last report earnings?

Harvard Bioscience last reported on Aug 11, 2026, covering fiscal Q2 2026.

### Did HBIO beat earnings estimates?

Yes. Harvard Bioscience reported EPS of −$0.14 for Q2 2026 against a −$0.21 estimate — a 33.33% beat.

### How much revenue did HBIO report last quarter?

Harvard Bioscience reported $22.7M in revenue for Q2 2026, against a consensus estimate of $21.4M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).